Press Release
Stockholm, June 3, 2008
Diamyd kicks off recruitment campaign for Phase III in the US
Diamyd Medical AB (publ.) initiates the campaign for Phase III recruitment in the US, by exhibiting at the ADA conference in San Francisco 6th - 10th of June 2008.
ADA, American Diabetes Association 68th Scientific Sessions, is the world's largest exposition of diabetes-related products, services, and technology. More than 13,000 top scientists, physicians and other health care professionals from around the world will share cutting-edge research, treatment recommendations and advances toward a cure for diabetes.
"The ADA conference is an excellent opportunity for us to meet and talk to specialists in our field" says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are focusing on information to specialists about the Phase III trials for the therapeutic diabetes vaccine Diamyd®, and we are also marketing Diamyd Medical and strengthening our brand as a committed diabetes company".
Also attending the ADA conference is Professor Jerry Palmer, Lead Investigator for the Diamyd® Phase III trial in the US. Professor Palmer will chair a session called "Type 1 Diabetes Prevention".
For further information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB, elisabeth.lindner@diamyd.com
Phone: +46-8-661 00 26
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB, sonja.catani@diamyd.com
Phone: +46-8-661 00 26
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8 661 63 68
E-post: info@diamyd.com. VATno: SE556530-142001.
This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company´s most advanced project is the GAD-based drug Diamyd® for type 1 diabetes and for which Phase III trials have been initiated in both the US and Europe. Furthermore the company has initiated clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson´s disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company´s web site: www.diamyd.com